Poly (adenosine 5′-diphosphate-ribose) polymerase inhibitors (PARPi) have significantly improved maintenance therapy for recurrent ovarian cancer and are now approved as a first-line treatment for women with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations [3–14]. This evidence concerns the gene BRCA1 and ovarian carcinoma.